MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of seven clinical implantations of its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty. The surgeries were performed in Denmark and Ireland, with all patients recovering well post-operation.
VitaFlow Liberty: A Pioneer in TAVI Systems
VitaFlow Liberty is touted as the world’s first and only electrically recyclable TAVI system. Initially approved in China in August 2021, it has since been registered in Argentina, Colombia, Thailand, and Russia. The device is anticipated to become the first domestically developed TAVI product to receive the CE mark, a significant step towards global recognition and market access.
Performance and Overseas Applications
VitaFlow Liberty has demonstrated excellent performance in nearly 200 overseas commercial applications, showcasing its release stability, precise positioning capabilities, perivalve leakage prevention, and superior hemodynamic performance. These attributes position the device as a leading option in the treatment of aortic valve conditions, offering a promising alternative for patients and healthcare providers.-Fineline Info & Tech
